Successful outbreak responses depend on reliable data.

Missed the webinar? Watch it now!

Eight key lessons for COVID-19

that we've learned from previous outbreaks.

As a trusted partner in 60+ countries,

we stay two steps ahead, ready to launch studies in weeks.

"The FHI Clinical project management team has provided clear and informative guidance on expected processes and standards for rigorous clinical trial oversight...and has been a good partner in our spatial repellent studies."

—Nicole L. Achee, PhD, Eck Institute for Global Health,
University of Notre Dame

previous arrow
previous arrow
next arrow
next arrow
Slider

We manage complex clinical research in resource-limited settings

We envision a world where advances in vaccines and medicines help all people live longer, healthier lives.

we are fhi clinical

Global Expertise

We offer a unique combination of in-country technical, regulatory and cultural knowledge and an established global presence in Africa, Asia, Europe, Latin America and North America.

Responsive Approaches

We adapt our processes and workflow as your study needs change. No matter how large or small the project, we remain agile and exact, because your research demands it.

Proven Solutions

We have research at our core. A subsidiary of FHI 360, we benefit from our parent company’s 40+ year history of clinical research and success in creating and growing CROs.

put our experience to work for you

Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines.
Let us help you enter hard-to-reach markets and access the right patient populations.

Tailored Services

Tailored services to meet your needs, from protocol design and site assessments to trial planning, implementation and management.

Therapeutic Expertise

Ability to address challenges across dozens of therapeutic areas, including infectious diseases (IDs), neglected tropical diseases (NTDs), emerging and reemerging diseases, and pediatric studies.

Established Partnerships

Leverage established partnerships with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Agency for International Development (USAID).

Monitoring COVID-19

As we monitor the rapidly changing COVID-19 situation, reliable data sources are crucial. We recommend this resource from Johns Hopkins University to better understand the pandemic’s impact.

The data sources include the World Health Organization, the U.S. Centers for Disease Control and Prevention, the European Center for Disease Prevention and Control, the National Health Commission of the People’s Republic of China, 1point3acres, Worldometers.info, BNO, state and national government health departments, local media reports, and the DXY, one of the world’s largest online communities for physicians, health care professionals, pharmacies and facilities.

News

Remdesivir shows promising results for COVID-19 in preliminary analyses published in NEJM

Preliminary results of the Adaptive COVID-19 Treatment Trial (ACTT) investigating remdesivir for the treatment of COVID-19 in hospitalized adults with evidence of lower respiratory tract involvement has been published in the New England Journal of Medicine . Of the FHI Clinical study team members, Danielle Fisher, Clinical Research Project Manager, and Wendi McDonald, Associate Project Manager, are listed on the manuscript for her contributions to the study.

Read More »

Events

blog

Pandemic Experience Means Expert Guidance

When COVID-19 was declared a pandemic, the FHI Clinical team immediately grasped the challenges that the search for vaccines and treatments would present. We’ve been here before, addressing everything from the global threat of malaria to outbreaks of Ebola in West Africa, Zika in the Americas, and chikungunya in the Caribbean during the aftermath of Hurricane Maria. In this blog post, we describe the steps to take and the critical questions to ask.

Read More »